Actuate Therapeutics Inc Financials
This page shows Actuate Therapeutics Inc (ACTU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Actuate’s business still runs on cash burn, while share issuance and financing inflows are what strengthened the latest balance sheet.
Financing inflows of$23.7M were larger than the operating cash burn of$19.2M , so cash and liquidity improved even though the underlying operation still consumed cash at a heavy rate. That reliance on outside funding, rather than internal cash generation, is what allowed equity to rebuild to$7.9M and made the balance sheet materially less strained.
Net loss and cash burn moved together: a net loss of
Share count moved from 19.5M shares to 23.2M shares, reinforcing that outside capital rather than operations funded the business. R&D fell to
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Actuate Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Actuate Therapeutics Inc carries a low D/E ratio of 0.77, meaning only $0.77 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Actuate Therapeutics Inc's current ratio of 2.39 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Actuate Therapeutics Inc generates a -280.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -26189.0% the prior year.
Actuate Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Actuate Therapeutics Inc generates $0.86 in operating cash flow (-$19.2M OCF vs -$22.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Actuate Therapeutics Inc earns $-1110.9 in operating income for every $1 of interest expense (-$22.5M vs $20K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Actuate Therapeutics Inc reported -$22.2M in net income in fiscal year 2025. This represents an increase of 18.5% from the prior year.
Actuate Therapeutics Inc earned $-1.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 67.5% from the prior year.
Cash & Balance Sheet
Actuate Therapeutics Inc held $13.2M in cash against $0 in long-term debt as of fiscal year 2025.
Actuate Therapeutics Inc had 23M shares outstanding in fiscal year 2025. This represents an increase of 19.0% from the prior year.
Margins & Returns
Actuate Therapeutics Inc's ROE was -280.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25908.5 percentage points from the prior year.
Capital Allocation
Actuate Therapeutics Inc invested $10.3M in research and development in fiscal year 2025. This represents a decrease of 44.9% from the prior year.
ACTU Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.6M | N/A | $2.2M-21.2% | $2.8M-14.1% | $3.2M | N/A | $3.8M-14.1% | $4.4M |
| SG&A Expenses | $3.1M | N/A | $3.3M+2.8% | $3.2M+1.9% | $3.1M | N/A | $1.6M+53.9% | $1.1M |
| Operating Income | -$5.7M | N/A | -$5.5M+8.3% | -$6.0M+6.2% | -$6.4M | N/A | -$5.4M+0.8% | -$5.4M |
| Interest Expense | $5K | N/A | $5K0.0% | $5K0.0% | $5K | N/A | $3K-31.3% | $5K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.6M | N/A | -$5.4M+9.1% | -$5.9M+5.8% | -$6.3M | N/A | -$6.0M+9.1% | -$6.6M |
| EPS (Diluted) | $-0.24 | N/A | $-0.25+16.7% | $-0.30+6.3% | $-0.32 | N/A | $-0.55 | $-4.20 |
ACTU Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.9M-36.5% | $14.0M-20.8% | $17.7M+154.2% | $7.0M+55.5% | $4.5M-51.9% | $9.3M-34.7% | $14.3M+724.0% | $1.7M |
| Current Assets | $8.5M-37.6% | $13.6M-21.8% | $17.4M+160.8% | $6.7M+57.4% | $4.2M-53.9% | $9.2M-35.4% | $14.3M+2494.7% | $550K |
| Cash & Equivalents | $8.1M-38.2% | $13.2M-22.2% | $16.9M+160.7% | $6.5M+66.9% | $3.9M-55.0% | $8.6M-36.1% | $13.5M+3745.1% | $352K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.1M-16.1% | $6.1M-9.8% | $6.8M-29.6% | $9.6M+0.5% | $9.6M+3.9% | $9.2M+3.5% | $8.9M-92.3% | $116.0M |
| Current Liabilities | $4.7M-17.3% | $5.7M-10.4% | $6.4M-30.7% | $9.2M+0.5% | $9.2M+4.0% | $8.8M+3.6% | $8.5M-57.7% | $20.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.8M-52.2% | $7.9M-27.5% | $10.9M+512.1% | -$2.7M+47.8% | -$5.1M-4983.3% | $104K-98.1% | $5.4M+104.7% | -$114.3M |
| Retained Earnings | -$160.2M-3.6% | -$154.6M-3.0% | -$150.1M-3.7% | -$144.6M-4.3% | -$138.7M-4.8% | -$132.4M-5.1% | -$125.9M-5.0% | -$120.0M |
ACTU Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.0M-34.3% | -$3.7M+44.1% | -$6.7M-60.0% | -$4.2M+9.6% | -$4.6M+3.2% | -$4.8M+47.8% | -$9.1M-242.2% | -$2.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$8K+72.4% | -$29K-100.2% | $17.1M+152.5% | $6.8M+5177.3% | -$133K-22.0% | -$109K-100.5% | $22.3M+2232.3% | $957K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ACTU Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -148.7% | N/A | -49.5% | N/A | N/A | N/A | -111.4% | N/A |
| Return on Assets | -63.1% | N/A | -30.5%+54.8pp | -85.4%+55.5pp | -140.9% | N/A | -41.9%+337.9pp | -379.7% |
| Current Ratio | 1.80-0.6 | 2.39-0.3 | 2.74+2.0 | 0.73+0.3 | 0.46-0.6 | 1.05-0.6 | 1.68+1.7 | 0.03 |
| Debt-to-Equity | 1.35+0.6 | 0.77+0.2 | 0.62+4.2 | -3.63-1.7 | -1.88-90.3 | 88.44+86.8 | 1.66+2.7 | -1.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Actuate Therapeutics Inc profitable?
No, Actuate Therapeutics Inc (ACTU) reported a net income of -$22.2M in fiscal year 2025.
What is Actuate Therapeutics Inc's return on equity (ROE)?
Actuate Therapeutics Inc (ACTU) has a return on equity of -280.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Actuate Therapeutics Inc's operating cash flow?
Actuate Therapeutics Inc (ACTU) generated -$19.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Actuate Therapeutics Inc's total assets?
Actuate Therapeutics Inc (ACTU) had $14.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Actuate Therapeutics Inc spend on research and development?
Actuate Therapeutics Inc (ACTU) invested $10.3M in research and development during fiscal year 2025.
What is Actuate Therapeutics Inc's current ratio?
Actuate Therapeutics Inc (ACTU) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.
What is Actuate Therapeutics Inc's debt-to-equity ratio?
Actuate Therapeutics Inc (ACTU) had a debt-to-equity ratio of 0.77 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Actuate Therapeutics Inc's return on assets (ROA)?
Actuate Therapeutics Inc (ACTU) had a return on assets of -158.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Actuate Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Actuate Therapeutics Inc (ACTU) had $13.2M in cash against an annual operating cash burn of $19.2M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Actuate Therapeutics Inc's Piotroski F-Score?
Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Actuate Therapeutics Inc's earnings high quality?
Actuate Therapeutics Inc (ACTU) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Actuate Therapeutics Inc cover its interest payments?
Actuate Therapeutics Inc (ACTU) has an interest coverage ratio of -1110.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Actuate Therapeutics Inc?
Actuate Therapeutics Inc (ACTU) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.